Literature DB >> 19343140

Emerging molecular biology of pancreatic cancer.

Ralph H Hruban1, Anirban Maitra, Richard Schulick, Daniel Laheru, Joseph Herman, Scott E Kern, Michael Goggins.   

Abstract

Pancreatic cancer, like most other cancers, is fundamentally caused by mutations in specific genes. Many of the genes targeted in pancreatic cancer have been identified in the past decade, and an understanding of these genes and their function has helped identify familial forms of pancreatic cancer, define the precursor lesions from which invasive pancreatic cancers arise, and will soon lead to gene-specific therapies for this disease. This article reviews the tumor-suppressor genes, oncogenes, and DNA repair genes targeted in pancreatic cancer, and presents clinical applications based on our understanding of the genetic basis of pancreatic cancer.

Entities:  

Year:  2008        PMID: 19343140      PMCID: PMC2661541     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  67 in total

1.  PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Nancy T Ciau; Daniel J Ho; Xiaojun Li; John D Allendorf; Helen E Remotti; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

2.  Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p.

Authors:  S C Abraham; T T Wu; D S Klimstra; L S Finn; J H Lee; C J Yeo; J L Cameron; R H Hruban
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.

Authors:  Steven R Hustinx; Ralph H Hruban; Lorenzo M Leoni; Christine Iacobuzio-Donahue; John L Cameron; Charles J Yeo; Priscilla N Brown; Pedram Argani; Raheela Ashfaq; Noriyoshi Fukushima; Michael Goggins; Scott E Kern; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2005-01-15       Impact factor: 4.742

4.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Authors:  R E Wilentz; M Goggins; M Redston; V A Marcus; N V Adsay; T A Sohn; S S Kadkol; C J Yeo; M Choti; M Zahurak; K Johnson; M Tascilar; G J Offerhaus; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

5.  In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

Authors:  Michiel S van der Heijden; Jonathan R Brody; David A Dezentje; Eike Gallmeier; Steven C Cunningham; Michael J Swartz; Angelo M DeMarzo; G Johan A Offerhaus; William H Isacoff; Ralph H Hruban; Scott E Kern
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

Review 6.  Molecular pathology of pancreatic cancer.

Authors:  R H Hruban; C Iacobuzio-Donahue; R E Wilentz; M Goggins; S E Kern
Journal:  Cancer J       Date:  2001 Jul-Aug       Impact factor: 3.360

7.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas.

Authors:  B A Ruggeri; L Huang; M Wood; J Q Cheng; J R Testa
Journal:  Mol Carcinog       Date:  1998-02       Impact factor: 4.784

8.  Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families.

Authors:  H T Lynch; R E Brand; J F Lynch; R M Fusaro; T C Smyrk; M Goggins; S E Kern
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

9.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

10.  The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer.

Authors:  George Zogopoulos; Heidi Rothenmund; Ayelet Eppel; Colleen Ash; Mohammad Reza Akbari; David Hedley; Steven A Narod; Steven Gallinger
Journal:  Hum Genet       Date:  2007-04-06       Impact factor: 4.132

View more
  13 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

Authors:  Yong Gao; Zhiliang Jia; Xiangyu Kong; Qiang Li; David Z Chang; Daoyan Wei; Xiangdong Le; Huang Suyun; Shengdong Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2011-06-14       Impact factor: 12.701

3.  Diabetes Type 2 and Pancreatic Cancer: A History Unfolding.

Authors:  Andre De Souza; Khawaja Irfan; Faisal Masud; Muhammad Wasif Saif
Journal:  JOP       Date:  2016-03

Review 4.  Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma.

Authors:  Daniel Pietrasz; Elisabetta Sereni; Francesco Lancelotti; Antonio Pea; Claudio Luchini; Giulio Innamorati; Roberto Salvia; Claudio Bassi
Journal:  Br J Cancer       Date:  2022-02-23       Impact factor: 9.075

5.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

Review 6.  Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Authors:  Georg Feldmann; Anirban Maitra
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

7.  SMURF1 amplification promotes invasiveness in pancreatic cancer.

Authors:  Kevin A Kwei; A Hunter Shain; Ryan Bair; Kelli Montgomery; Collins A Karikari; Matt van de Rijn; Manuel Hidalgo; Anirban Maitra; Murali D Bashyam; Jonathan R Pollack
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

Review 8.  Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.

Authors:  Elena Gabriela Chiorean; Andrew L Coveler
Journal:  Drug Des Devel Ther       Date:  2015-07-07       Impact factor: 4.162

9.  Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

Authors:  Zhe Chang; Huaiqiang Ju; Jianhua Ling; Zhuonan Zhuang; Zhongkui Li; Huamin Wang; Jason B Fleming; James W Freeman; Dihua Yu; Peng Huang; Paul J Chiao
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

10.  Familial pancreatic cancer.

Authors:  Henry T Lynch; Jane F Lynch; Stephen J Lanspa
Journal:  Cancers (Basel)       Date:  2010-11-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.